Ovid Therapeutics appoints Dr. Kevin Fitzgerald as director, grants stock options

Ovid Therapeutics Inc.

Appointed Dr. Kevin Fitzgerald, Ph.D. to Board as Class II director effective Oct 6, 2021.
Initial option for 30,000 shares at $3.44 exercise price, vesting monthly over 3 years.
Annual cash compensation of $40,000 prorated; eligible for 15,000-share annual option grant.
No arrangements or understandings with any other person regarding appointment; no family relationships.
Standard indemnity agreement entered; compensation per Non-Employee Director Compensation Policy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Kevin Fitzgerald

director

OVID · Ovid Therapeutics Inc.

Effective: 2021-10-06
Filed: October 7, 2021, 7:59 PM ET

On October 6, 2021, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”), the Board appointed Dr. Kevin Fitzgerald, Ph.D. as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Kevin Fitzgerald was appointed as director at Ovid Therapeutics Inc..

Action: appointed
Role: director

Exact text from the filing

On October 6, 2021, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”), the Board appointed Dr. Kevin Fitzgerald, Ph.D. as a director of the Company, effective immediately.

View on SEC.gov

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-050376

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.